keyword
MENU ▼
Read by QxMD icon Read
search

Serostim

keyword
https://www.readbyqxmd.com/read/18828236/the-next-generation-of-human-growth-hormone-how-serostim-and-tesamorelin-measure-up
#1
Brett Grodeck
No abstract text is available yet for this article.
September 2008: Positively Aware: the Monthly Journal of the Test Positive Aware Network
https://www.readbyqxmd.com/read/18753120/treatment-of-altered-body-composition-in-hiv-associated-lipodystrophy-comparison-of-rosiglitazone-pravastatin-and-recombinant-human-growth-hormone
#2
RANDOMIZED CONTROLLED TRIAL
Derek C Macallan, Christine Baldwin, Sundihya Mandalia, Vjera Pandol-Kaljevic, Nadine Higgins, Alan Grundy, Graeme J Moyle
PURPOSE: Treatment options for HIV-associated lipodystrophy syndrome (HALS) remain limited. The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS. METHOD: Sixty-four subjects received daily rosiglitazone (4 mg, n = 14), pravastatin (40 mg, n = 11), or rosiglitazone plus pravastatin (n = 13) for 48 weeks or recombinant human growth hormone (rhGH; Serostim 2 mg, 12 weeks, n = 13) alone or combined with rosiglitazone (n = 13)...
July 2008: HIV Clinical Trials
https://www.readbyqxmd.com/read/17592343/recombinant-human-growth-hormone-to-treat-hiv-associated-adipose-redistribution-syndrome-12-week-induction-and-24-week-maintenance-therapy
#3
RANDOMIZED CONTROLLED TRIAL
Carl Grunfeld, Melanie Thompson, Stephen J Brown, Gary Richmond, Daniel Lee, Norma Muurahainen, Donald P Kotler et al.
BACKGROUND: HIV-associated adipose redistribution syndrome (HARS) is an HIV-associated disorder characterized by excess truncal fat, including visceral adipose tissue (VAT). METHODS: From baseline to week 12 in this randomized, double-blind, placebo (PL)-controlled, multicenter trial investigating effects of recombinant human growth hormone (r-hGH; Serostim; EMD Serono Inc., Rockland, MA) in patients with HARS, 325 received induction (4 mg/d of r-hGH) or PL. At week 12, patients who initially received induction were rerandomized to 2 mg of r-hGH on alternate days (maintenance) or PL to week 36...
July 1, 2007: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/16724867/spotlight-on-mammalian-cell-derived-somatropin-in-hiv-associated-wasting
#4
REVIEW
David R Goldsmith, Antona J Wagstaff
HIV-associated wasting, characterized by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy. Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant human growth hormone) derived from mammalian cells (Serostim) is the only US FDA-approved treatment indicated to increase lean body mass, bodyweight, and physical endurance in HIV-associated wasting. Somatropin 0.1 mg/kg/day administered subcutaneously for 12 weeks effectively increased work output, bodyweight, and lean body mass, and improved health-related quality of life, compared with placebo, and had a generally manageable tolerability profile in a large randomized study in patients with HIV-associated wasting...
2006: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/16526830/mammalian-cell-derived-somatropin-a-review-of-its-use-in-the-management-of-hiv-associated-wasting
#5
REVIEW
David R Goldsmith, Antona J Wagstaff
HIV-associated wasting, characterised by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy (HAART). Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant human growth hormone) derived from mammalian cells (Serostim) is the only US FDA-approved treatment indicated to increase lean body mass, bodyweight and physical endurance in HIV-associated wasting. Somatropin 0...
2006: Drugs
https://www.readbyqxmd.com/read/15076238/effects-of-growth-hormone-on-abnormal-visceral-adipose-tissue-accumulation-and-dyslipidemia-in-hiv-infected-patients
#6
RANDOMIZED CONTROLLED TRIAL
Donald P Kotler, Norma Muurahainen, Carl Grunfeld, Christine Wanke, Melanie Thompson, Michael Saag, Daena Bock, Gregg Simons, Joseph M Gertner et al.
BACKGROUND: Some HIV-infected patients develop fat maldistribution with visceral adipose tissue (VAT) accumulation and metabolic abnormalities. No medical treatment is approved by the US Food and Drug Administration to reduce VAT. METHODS: In this double-blind trial, 245 HIV-infected patients with excess VAT were randomized to receive placebo (PL), recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD) or 4 mg on alternate days (AD) for 12 weeks. For weeks 12 to 24, DD patients were rerandomized to PL (DD-PL) or AD (DD-AD), AD patients continued on AD (AD-AD), and PL patients were switched to DD (PL-DD)...
March 1, 2004: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/12647692/fda-notifications-watch-for-counterfeit-lot-of-serostim
#7
(no author information available yet)
No abstract text is available yet for this article.
August 2002: AIDS Alert
https://www.readbyqxmd.com/read/12422825/when-medi-cal-says-no-to-serostim
#8
Leslie Kline-Capelle
No abstract text is available yet for this article.
September 2002: Positive Living
https://www.readbyqxmd.com/read/12238474/a-needle-free-delivery-of-serostim
#9
Marcya G Owens
No abstract text is available yet for this article.
July 2002: Survival News: the Monthly Publication of AIDS Survival Project
https://www.readbyqxmd.com/read/12194732/counterfeit-serostim
#10
(no author information available yet)
No abstract text is available yet for this article.
July 2002: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/12085844/counterfit-drugs-check-combivir-serostim-epogen
#11
John S James
No abstract text is available yet for this article.
May 31, 2002: AIDS Treatment News
https://www.readbyqxmd.com/read/11548491/counterfeit-version-of-serostim-investigated-by-fda
#12
(no author information available yet)
No abstract text is available yet for this article.
February 2001: Positive Living
https://www.readbyqxmd.com/read/11547414/danger-counterfeit-serostim-human-growth-hormone
#13
(no author information available yet)
No abstract text is available yet for this article.
May 25, 2001: AIDS Treatment News
https://www.readbyqxmd.com/read/11486725/serono-initiates-clinical-trial-of-serostim-for-aids-related-metabolic-complication
#14
(no author information available yet)
No abstract text is available yet for this article.
July 2001: Journal of the Association of Nurses in AIDS Care: JANAC
https://www.readbyqxmd.com/read/11363832/aids-activists-secure-approval-for-human-growth-hormone-serostim
#15
(no author information available yet)
No abstract text is available yet for this article.
1996: Critical Path AIDS Project
https://www.readbyqxmd.com/read/8967667/recombinant-human-growth-hormone-in-patients-with-hiv-associated-wasting-a-randomized-placebo-controlled-trial-serostim-study-group
#16
RANDOMIZED CONTROLLED TRIAL
M Schambelan, K Mulligan, C Grunfeld, E S Daar, A LaMarca, D P Kotler, J Wang, S A Bozzette, J B Breitmeyer
BACKGROUND: Body wasting, particularly loss of body cell mass, is an increasingly prevalent acquired immunodeficiency syndrome (AIDS)-defining condition and is an independent risk factor for death in patients infected with the human immunodeficiency virus (HIV). Treatment with growth hormone for 7 days resulted in weight gain and nitrogen retention, but the long-term effects of this treatment in patients with HIV-associated wasting are not known. OBJECTIVE: To evaluate the long-term effect of treatment with growth hormone on weight, body composition, functional performance, and quality of life in patients with HIV-associated wasting...
December 1, 1996: Annals of Internal Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"